CollPlant is a vertically-integrated regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.
CollPlant’s revolutionary plant-based technology is the only commercially viable technology for mass production of Type I recombinant human (rhCollagen), which is identical to the collagen produced by the human body. Leveraging on the unique properties of rhCollagen and biomaterial know-how, CollPlant is developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.
CollPlant’s rhCollagen is the ideal building block for regenerative medicine applications, and the key component in BioInks for 3D bioprinting of tissues and organs. CollPlant is developing series of rhCollagen- based BioInk compositions including ECM components and synthetic polymers. In addition to BioInks CollPlant is also developing implants for soft tissue reconstruction such as regenerative breast implants and dermal fillers. CollPlant BioInks are produced from sustainable and scalable processes, and can be expressed through a variety of 3D hardware platforms including 3D printers and electrospinning.
CollPlant was introduced to ARMI by their collaborators at Lung Biotechnology, fellow ARMI members. “One of the key challenges in regenerative medicine is advancing new technologies from the bench level to industrial level,” said Yehiel Tal, CollPlant Chief Executive Officer. “ARMI’s mission is supporting this need by creating a platform that is comprised of companies with innovative technologies and manufacturing expertise, that can jointly address this challenge. We see the value of working inside of a larger technical ecosystem.”
Tal said “We are interested in being exposed to the most recent developments in regenerative medicine, advance collaborations with other ARMI member companies, attend the standards committees, and attend the regulatory committees to help in forming the new draft guidance for 3D Bioprinting.”
In turn, Tal said that CollPlant will bring its expertise in regenerative medicine technologies and products development, including its rhCollagen as a key component in tissue and organ manufacturing, as well as downstream processing techniques to the ARMI ecosystem.
Tal believes we’ll need to overcome some barriers within the regenerative medicine industry in the next 5-10 years, including scaffold vascularization; cells perfusion; 3D bioprinting accuracy; control of construct physical properties; 3D bioprinting throughput, and real-time process control. This will enable to large scale manufacturing of organs and tissues in high yield and competitive cost.
Tal concluded “CollPlant is open to strategic collaborations in the field of regenerative medicine, and we believe CollPlant’s versatile BioInk platform will serve a wide range of applications”.